What is Global Pruritus Therapeutics Market?
The Global Pruritus Therapeutics Market is a comprehensive study of the global market trends and growth prospects in the field of pruritus therapeutics. Pruritus, also known as itching, is a common symptom of various dermatological diseases. The market for pruritus therapeutics includes treatments for conditions like dermatitis, psoriasis, and prurigo nodularis. The global market for these treatments was valued at US$ 14270 million in 2022. It is projected to reach a value of US$ 18060 million by 2029, growing at a Compound Annual Growth Rate (CAGR) of 4.0% from 2023 to 2029. This growth is driven by the increasing prevalence of skin diseases and the development of new treatments. The market is dominated by major players such as J&J, Abbott, Amgen, and LEO Pharma, which collectively hold about 60% of the market share. The largest market for pruritus therapeutics is North America, which accounts for nearly 43% of the global revenue.
Antihistamines, Corticosteroids, Calcineurin Inhibitors, Others in the Global Pruritus Therapeutics Market:
The Global Pruritus Therapeutics Market is segmented based on the type of treatment, which includes antihistamines, corticosteroids, calcineurin inhibitors, and others. Antihistamines are commonly used to treat pruritus. They work by blocking histamine, a substance in the body that causes allergic symptoms. Corticosteroids are anti-inflammatory medicines that are often used to treat skin conditions that cause itching. Calcineurin inhibitors are a type of immunosuppressant that are used to treat severe atopic dermatitis, a type of eczema that causes intense itching. Other treatments for pruritus include emollients, which moisturize the skin and reduce itching, and phototherapy, which uses ultraviolet light to reduce inflammation and itching. These treatments are used in various combinations, depending on the severity and type of pruritus.
External Use, Oral, Injection in the Global Pruritus Therapeutics Market:
The Global Pruritus Therapeutics Market is also segmented based on the method of administration, which includes external use, oral, and injection. External use involves applying a cream or ointment directly to the affected area. This is often the first line of treatment for pruritus, as it can provide immediate relief from itching. Oral treatments are usually prescribed for more severe or persistent pruritus. These can include antihistamines, corticosteroids, or other medications. Injections are typically reserved for the most severe cases of pruritus, where other treatments have not been effective. They can deliver a high dose of medication directly to the affected area, providing rapid relief from itching.
Global Pruritus Therapeutics Market Outlook:
In summary, the Global Pruritus Therapeutics Market is a growing market with significant potential for future growth. The market is driven by the increasing prevalence of skin diseases and the development of new treatments. Major players in the market include J&J, Abbott, Amgen, and LEO Pharma. The largest market for pruritus therapeutics is North America. The market is segmented based on the type of treatment and the method of administration. Treatments include antihistamines, corticosteroids, calcineurin inhibitors, and others, and can be administered externally, orally, or by injection.
| Report Metric | Details |
| Report Name | Pruritus Therapeutics Market |
| Accounted market size in 2022 | US$ 14270 in million |
| Forecasted market size in 2029 | US$ 18060 million |
| CAGR | 4.0% |
| Base Year | 2022 |
| Forecasted years | 2023 - 2029 |
| Segment by Type |
|
| Segment by Application |
|
| By Region |
|
| By Company | J&J, Abbott, Amgen, LEO Pharma, Novartis, Bayer, Pfizer, UCB Pharma, GlaxoSmithKline, Galderma, Huapont |
| Forecast units | USD million in value |
| Report coverage | Revenue and volume forecast, company share, competitive landscape, growth factors and trends |
